Home    Back

Nbi-74788    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
81Congenital adrenal hyperplasia7

81. Congenital adrenal hyperplasia    [ 65 clinical trials,   77 drugs,   (DrugBank: 20 drugs),   11 drug target genes,   65 drug target pathways]
Searched query = "Congenital adrenal hyperplasia", "Congenital adrenal enzyme deficiency", "Congenial adrenal cortex enzyme deficiency", "Congenital Lipoid Adrenal Hyperplasia", "3β-Hydroxysteroid Dehydrogenase Deficiency", "21-Hydroxylase deficiency", "11β-Hydroxylase deficiency", "17α-Hydroxylase deficiency", "P450 oxidoreductase deficiency", "Aldosterone synthase deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
7 / 65 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2019-004873-17-PL
(EUCTR)		01/12/202003/07/2020A study of safety and efficacy of NBI-74788 in Classic Congenital Adrenal HyperplasiaA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment Classic Congenital Adrenal Hyperplasia (CAH)
MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Product Name: Crinecerfont
Product Code: NBI-74788
INN or Proposed INN: Crinecerfont		Neurocrine Biosciences, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		165Phase 3United States;Portugal;Czechia;Greece;Spain;Austria;United Kingdom;Italy;France;Poland;Belgium;Bulgaria;Germany;Netherlands;Sweden
2EUCTR2019-004873-17-GB
(EUCTR)		15/10/202030/04/2020A study of safety and efficacy of NBI-74788 in Classic Congenital Adrenal HyperplasiaA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment Classic Congenital Adrenal Hyperplasia (CAH)
MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Product Name: Crinecerfont
Product Code: NBI-74788
INN or Proposed INN: Crinecerfont		Neurocrine Biosciences, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		165Phase 3United States;Portugal;Greece;Spain;Austria;United Kingdom;Italy;France;Czech Republic;Belgium;Poland;Bulgaria;Germany;Netherlands;Sweden
3EUCTR2019-004873-17-PT
(EUCTR)		12/10/202030/06/2020A study of safety and efficacy of NBI-74788 in Classic Congenital Adrenal HyperplasiaA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment Classic Congenital Adrenal Hyperplasia (CAH)
MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Product Name: Crinecerfont
Product Code: NBI-74788
INN or Proposed INN: Crinecerfont		Neurocrine Biosciences, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		165Phase 3Italy;France;Czech Republic;Poland;Belgium;Bulgaria;Netherlands;Germany;Sweden;Portugal;United States;Greece;Spain;Austria;United Kingdom
4EUCTR2019-004873-17-GR
(EUCTR)		29/07/202030/07/2020A study of safety and efficacy of NBI-74788 in Classic Congenital Adrenal HyperplasiaA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment Classic Congenital Adrenal Hyperplasia (CAH)
MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Product Name: Crinecerfont
Product Code: NBI-74788
INN or Proposed INN: Crinecerfont		Neurocrine Biosciences, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		165Phase 3Portugal;United States;Greece;Spain;Austria;United Kingdom;Italy;France;Czech Republic;Poland;Belgium;Bulgaria;Germany;Netherlands;Sweden
5NCT04490915
(ClinicalTrials.gov)		July 23, 202024/7/2020Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal HyperplasiaA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label TreatmentCongenital Adrenal HyperplasiaDrug: Crinecerfont;Drug: PlaceboNeurocrine BiosciencesNULLRecruiting18 YearsN/AAll165Phase 3United States
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT04045145
(ClinicalTrials.gov)		September 11, 201931/7/2019Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Pediatric Subjects With Congenital Adrenal HyperplasiaA Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Pediatric Subjects With Congenital Adrenal HyperplasiaCAH - Congenital Adrenal HyperplasiaDrug: NBI-74788Neurocrine BiosciencesNULLRecruiting14 Years17 YearsAll12Phase 2United States
7NCT03525886
(ClinicalTrials.gov)		April 10, 20182/5/2018Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal HyperplasiaA Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adult Subjects With Congenital Adrenal HyperplasiaCAH - Congenital Adrenal HyperplasiaDrug: NBI-74788Neurocrine BiosciencesNULLCompleted18 Years50 YearsAll18Phase 2United States

Back to top